T. Rowe Price Associates
BVS icon

T. Rowe Price Associates’s Bioventus BVS Stock Holding History

T. Rowe Price Associates’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$363K Buy
38,404
+1,593
+4% +$15.2K ﹤0.01% 2766
2026
Q1 		$337K Buy
36,811
+12,163
+49% +$102K ﹤0.01% 2631
2025
Q4 		$184K Hold
24,648
– – ﹤0.01% 2834
2025
Q3 		$165K Buy
24,648
+1,963
+9% +$13.6K ﹤0.01% 2829
2025
Q2 		$151K Buy
22,685
+5,276
+30% +$37.4K ﹤0.01% 2801
2025
Q1 		$160K Buy
17,409
+2,215
+15% +$22.1K ﹤0.01% 2714
2024
Q4 		$160K Buy
15,194
+3,153
+26% +$37.3K ﹤0.01% 2754
2024
Q3 		$144K Hold
12,041
– – ﹤0.01% 2755
2024
Q2 		$0 Buy
+12,041
New +$66.1K ﹤0.01% 2940
2023
Q4 		– Sell
-62,679
Closed -$207K – 2909
2023
Q3 		$207K Buy
+62,679
New +$220K ﹤0.01% 2490
2021
Q4 		– Sell
-2,674,299
Closed -$37.9M – 2987
2021
Q3 		$37.9M Buy
+2,674,299
New +$41.2M ﹤0.01% 1110

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's BVS Position: Q2 2026 in Review

T. Rowe Price Associates increased its Bioventus (BVS) stake by 4.3% in Q2 2026, buying an estimated $15.2K and bringing the position to 38,404 shares worth $363K. The position accounts for ﹤0.01% of the portfolio, ranked #2766.

T. Rowe Price Associates first reported a position in BVS in Q3 2021 and has held it in 11 quarters since. The position peaked at $37.9M in Q3 2021. 157 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

  • T. Rowe Price Associates held 38,404 shares of Bioventus worth $363K as of Q2 2026.
  • T. Rowe Price Associates bought 1,593 Bioventus shares in Q2 2026, an estimated $15.2K.
  • Bioventus made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2766 holding.
  • T. Rowe Price Associates first reported a position in Bioventus in Q3 2021 and has held it in 11 quarters since.
  • T. Rowe Price Associates's Bioventus position peaked at $37.9M in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.